These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29362167)

  • 1. The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review.
    Anderson LJ; Shekelle P; Keeler E; Uscher-Pines L; Shanman R; Morton S; Aliyev G; Nuckols TK
    Am J Prev Med; 2018 Feb; 54(2):299-315. PubMed ID: 29362167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
    Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
    JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS; Davis MM
    Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
    Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
    Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    Nichol KL
    Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Program cost analysis of influenza vaccination of health care workers in Albania.
    Pallas SW; Ahmeti A; Morgan W; Preza I; Nelaj E; Ebama M; Levin A; Lafond KE; Bino S
    Vaccine; 2020 Jan; 38(2):220-227. PubMed ID: 31669063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program-Results from a randomized controlled trial.
    Yoo BK; Humiston SG; Szilagyi PG; Schaffer SJ; Long C; Kolasa M
    BMC Health Serv Res; 2015 Nov; 15():511. PubMed ID: 26573461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64 years old.
    Raj SM; Chughtai AA; Sharma A; Tan TC; MacIntyre CR
    Vaccine; 2019 Sep; 37(40):5979-5985. PubMed ID: 31473001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.
    Gatwood J; Meltzer MI; Messonnier M; Ortega-Sanchez IR; Balkrishnan R; Prosser LA
    Drugs; 2012 Jan; 72(1):35-48. PubMed ID: 22191794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
    de Boer PT; Backer JA; van Hoek AJ; Wallinga J
    BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required.
    Newall AT; Dehollain JP
    Vaccine; 2014 Mar; 32(12):1323-5. PubMed ID: 24486359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.
    Ott JJ; Klein Breteler J; Tam JS; Hutubessy RC; Jit M; de Boer MR
    Hum Vaccin Immunother; 2013 Jul; 9(7):1500-11. PubMed ID: 23732900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children.
    Yoo BK; Schaffer SJ; Humiston SG; Rand CM; Goldstein NPN; Albertin CS; Concannon C; Szilagyi PG
    BMC Health Serv Res; 2019 Jun; 19(1):407. PubMed ID: 31234842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.
    Gibson E; Begum N; Sigmundsson B; Sackeyfio A; Hackett J; Rajaram S
    Hum Vaccin Immunother; 2016 May; 12(5):1202-16. PubMed ID: 26837602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.